PCR and Flow Cytometric Analysis of Paclitaxel-inhibited Arylamine N-Acetyltransferase Activity and Gene Expression in Human Osteogenic Sarcoma Cells (U-2 OS)

Anticancer Research

Volumn 24, Issue 1, 2004, Pages 83-90

  Lu, Ko Hsiu ^a,b   Wang, Der Yean ^c   Lue, Ko Huang ^b   Hsiao, Yie Ming ^a   Chou, Ming Chih ^b   Chen, Yi Shuan ^d   Chung, Jing Gung ^d,e  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NONE   (Taiwan)

Author keywords

2 aminofluorene DNA adduct; N acetyltransferase; Osteogenic sarcoma; Paclitaxel

Indexed keywords

2 FLUORENYLAMINE; 4 AMINOBENZOIC ACID; ARYLAMINE ACETYLTRANSFERASE; MESSENGER RNA; PACLITAXEL;

ACETYLATION; ADOLESCENT; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; DNA ADDUCT; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

2-ACETYLAMINOFLUORENE; 4-AMINOBENZOIC ACID; ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYLAMINE N-ACETYLTRANSFERASE; BONE NEOPLASMS; CELL LINE, TUMOR; CYTOSOL; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; FLUORENES; GENE EXPRESSION; HUMANS; OSTEOSARCOMA; PACLITAXEL; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 1442350556     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Miller EC and Miller JA: Searches for the ultimate chemical carcinogens and their reaction with cellular macromolecules. Cancer 47: 2327-2345, 1981.
2. Lower GM: Concepts in causality: chemically induced human urinary bladder cancer. Cancer (Phila) 49: 1056-1066, 1982.
3. Dipple A, Michejda CJ and Weisburger EK: Metabolism of chemical carcinogens. Pharmacol Ther 27: 265-296, 1985.
4. Weber WW: The Acetylator Genes and Drug Response. Oxford University Press, New York. 1987, pp 21-55.
5. Flammang TJ and Kadlubar FF: Acetyl coenzyme A-dependent metabolic activation of N-hydroxy-3,2'-dimethyl-4-aminobiphenyl and several carcinogenic N-hydroxy arylamines in relation to tissue and species differences, other acyl donors, and arylhydroxamic acid-dependent acyltransferase. Carcinogenesis (Lond) 7: 919-926, 1986.
6. Neumann HG: The role of DNA damage in chemical carcinogenesis of aromatic amines. J Cancer Res Clin Oncol 112: 100-106, 1986.
7. Kadlubar FF: DNA adducts of carcinogenic aromatic amines. In: Hemminki K, Dipple A, Shuker DEG, Kadlubar FF, Segerback D and Bartsch H, eds, DNA Adducts, Identification and Biological Significance. IARC Scientific Publication, Lyon: IARC 125: 199-216, 1994.
8. Dipple A: DNA adducts of chemical carcinogens. Carcinogenesis (Lond) 16: 437-441, 1996.
9. Weber WW and Hein DW: N-Acetylation pharmacogenetics. Pharmacol Rev 37: 25-79, 1985.
10. Hein DW: Acetylator genotype and arylamine-induced carcinogenesis. Biochem Biophys Acta 948: 37-66, 1988.
11. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E and Kahn MA: Role of N-acetyltransferase phenotype in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet 2: 842-846, 1982.
12. Lang NP, Chu DZ, Hunter CF, Kendall DC, Flammang TJ and Kadlubar FF: Role of aromatic amines acetyltransferase in human colorectal cancer. Arch Surg 121: 1259-1261, 1986.
13. Ilett KF, David BM, Detchon P, Castleden WM and Kwa R: Acetylator phenotype in colorectal carcinoma. Cancer Res 47: 1466-1469, 1987.
14. Blum M, Grant DM, McBride W, Heim M and Myere UA: Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 9: 193-203, 1990.
15. Ohsako S and Deguchi T: Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferase from human liver. J Biol Chem 265: 4630-4636, 1990.
16. Ebisawa T and Deguchi T: Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferase. Biochem Biophys Res Comun 177: 1252-1257, 1991.
17. Grant DM, Blum M, Beer M and Meyer UA: Monomorphic and polymorphic human arylamine N-acetyltransferase: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39: 184-191, 1991.
18. Ho CC, Lin TH, Lai YS, Chung JG, Levy GN and Weber WW: Kinetics of acetyl coenzyme A: arylamine N-acetyltransferase from rapid and slow acetylator frog tissues. Drug Metab Dispos 24: 137-141, 1996.
19. Wani MC, Taylor HL and Wall ME: Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325-2332, 1971.
20. Donebower RC and Rowinsky EK: Paclitaxel. In: PPO Updates Vol 8-Prin Prac Oncol 10: 1-6, 1994.
21. Hsia TC, Chung JG, Lu HF, Ho HC, Yang CC, Lu KH and Hung CF: The effect of paclitaxel on 2-aminofluorene-DNA adducts formation and arylamine N-acetyltransferase activity and gene expression in human lung tumor cells (A549). Food Chem Toxicol 40: 697-703, 2002.
22. Lu KH, Lin KL, Yang CC, Hsia TC, Hsiao YM, Chou MC, Ho HC and Chung JG: The effect of paclitaxel on gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cells. Food Chem Toxicol 40: 705-713, 2002.
23. Chung JG, Chang HL, Lin WC, Wang HH, Yeh CC, Hung CF and Li YC: Inhibitory of N-acetyltransferase activity and DNA-2-aminofluorene adducts by glycyrrhizic acid in human colon tumour cells. Food Chem Toxicol 38: 163-172, 2000.
24. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
25. Levy GN and Weber WW: 2-Aminofluorene-DNA adduct formation in acetylator congenic mouse lines. Carcinogenesis 10: 705-709, 1989.
26. Levy GN, Chung JG and Weber WW: 2-Aminofluorene metabolism and DNA adduct formation by mononuclear leukocytes from rapid and slow acetylator mouse strains. Carcinogenesis 15: 353-357, 1994.
27. Chung JG, Yeh KT, Wu SL, Hsu NY, Chen GW, Yeh YM and Ho HA: Novel transmembrane GTPase of non-small cell lung cancer identified by mRNA differential display. Cancer Res 15: 8873-8879, 2001.
28. Ponte P, Ng SY, Engel J, Gunning P and Kedes L: Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 12: 1687-1696, 1984.
29. Cleland WW: The statistical analysis of enzyme kinetic data. Adv Enzymol 29: 1-32, 1967.
30. Muggenburg BA, Mewhinney JA, Griffith WC, Hahn FF, McClellan RO, Boecker BB and Scott BR: Dose-response relationships for bone cancers from plutonium in dogs and people. Health Phys 44: 529-535, 1983.
31. Weber WW, Levy GN and Hein DW: Acetylation. In: Conjugation Reactions in Drug Metabolism (Mulder GJ, eds), Taylor and Francis, London 1990, pp 163-191.
32. Chung JG, Levy GN and Weber WW: Distribution of 2-aminofluorene and p-aminobenzoic acid N-acetyltransferase activity in tissues of C57BL/6J rapid and B6. A-Nats slow acetylator congenic mice. Drug Metab Dispos 21: 1057-1063, 1993.
33. Zubay GL, Parson WW and Vance DE: Principles of Biochemistry, Wm. C. Brown Publishers. 1995, pp 135-153.
34. Umemura T, Tokumo K, Sima H, Gebhardt R, Poirier MC and Williams GM: Dose response effects of 2-acetylaminofluorene on DNA damage, cytotoxicity, cell proliferation and neoplastic conversion in rat liver. Cancer Letts 73: 1-10, 1993.
35. Walpole AL, Williams MHC and Roberts DC: Tumours of the urinary bladder in dogs after ingestion of 4-aminodiphenyl. Br J Indust Med 11: 105-109, 1954.
36. Deichmann BW and Radomski JL: The carcinogenicity and metabolism of 2-naphthylamine and related compounds. Indian Med Surg 32: 161-166, 1963.
37. Donadio M, Manzin E, Berruti A, Bottini A, Gorzegno G, Danese S, DeFabiani E, Surobba MG, Lorusso V, Castiglione F, Moro G, Bertetto O, Bumma C and Dogliotti L: Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial. Cancer Chemother Pharmacol 47: 391-396, 2001.
38. Ferrari AC, Chachoua A, Singh H, Rosenthal M, Taneja S, Bednar M, Mandeli J and Muggia F: A phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. Cancer 91: 2039-2045, 2001.
39. Tomita M, Kurata H, Aoki Y, Tanaka K and Kazama JJ: Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. Anticancer Drugs 12: 485-487, 2001.
40. Einisto P, Watanabe M, Ishidate M and Nohmi T: Mutagenicity of 30 chemicals in S. Typhimurium possessing different nitroreductase or O-acetyltransferase activities. Mutation Res 259: 95-102, 1991.